Know Cancer

or
forgot password

Chemotherapy-induced Symptoms in Sarcoma Patients and the Impact of Tumor Burden


N/A
18 Years
N/A
Open (Enrolling)
Both
Soft Tissue Sarcoma

Thank you

Trial Information

Chemotherapy-induced Symptoms in Sarcoma Patients and the Impact of Tumor Burden


Inclusion Criteria:



- Patients who are receiving doxorubicin plus ifosfamide (AI)

Exclusion Criteria:

- There is no exclusion criteria

Type of Study:

Observational

Study Design:

Time Perspective: Prospective

Outcome Measure:

To determine the extent of symptom burden and quality of life in sarcoma patients receiving AI chemotherapy.

Outcome Time Frame:

2 years

Safety Issue:

No

Principal Investigator

Hussein Tawbi, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Pittsburgh

Authority:

United States: Food and Drug Administration

Study ID:

10-046

NCT ID:

NCT01136824

Start Date:

June 2010

Completion Date:

December 2015

Related Keywords:

  • Soft Tissue Sarcoma
  • Sarcoma
  • questionnaire
  • doxorubicin plus ifosfamide (AI)
  • Sarcoma

Name

Location
University of Pittsburgh, Hillman Cancer Center Pittsburgh, Pennsylvania  15232